Logical Therapeutics Raises $30 Million

Logical Therapeutics Inc., a Pittsburgh-based drug developer focused on inflammatory disease, has raised $30 million in Series B funding. SV Life Sciences led the deal, and was joined by Burrill & Co., Novo A/S, Sigvion Capital and seed backer PA Early Stage Partners. , which provided the seed funding for Logical in July, 2006. Logical Therapeutics is developing novel drugs to treat inflammatory diseases. As part of the deal, Logical Therapeutics will establish new headquarters near Boston. www.logicaltherapeutics.com